Immunotherapy plus chemo for lung cancer with brain metastases
Treatments studied
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of an immunotherapy drug (AK112) with standard chemotherapy as the first treatment for people with a certain type of lung cancer that has spread to the brain. It may help control the cancer by boosting your immune system to fight it, and the study will check how well it works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have stage IV non-squamous non-small cell lung cancer (a type of lung cancer) that has spread to the brain.
- Your tumor must not have certain gene changes (like EGFR, ALK, ROS1, BRAF, or RET), either from a prior test or you agree to provide a sample for testing.
- You must have at least one tumor that can be measured on a scan, and you must be able to have an MRI to check your brain.
- You must be in reasonably good health, able to care for yourself (performance status of 0 or 1), with a life expectancy of at least 12 weeks.
- You cannot have had any prior cancer treatment for this disease, and you must be willing to use effective birth control if you are able to have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ivonescimab combined with chemotherapy for people whose lung cancer has spread to the tissues around the brain and spinal cord (leptomeningeal metastasis) and who have already tried a targeted therapy that stopped working. The goal is to see if this combo can control the cancer better.
This trial tests a combination of low-dose radiation to the whole brain, immunotherapy, and chemotherapy given through a lumbar puncture. It is for people with lung cancer that has spread to the lining of the brain and has not responded to standard treatments.
This trial tests a combination treatment for cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis). It uses an antibody given directly into the spinal fluid along with a chemotherapy drug, with the goal of targeting the cancer more effectively.
This trial tests a combination of two experimental drugs, AK146D1 and AK112, for people with advanced non-small cell lung cancer that cannot be removed by surgery or treated with standard chemo-radiation. It aims to find out if this combination can shrink tumors or slow cancer growth.
This trial tests a new drug called AK112 for people with a certain type of advanced lung cancer that has specific gene changes (like EGFR or ALK) and where previous targeted therapy pills stopped working. It is a phase 2 study, so it helps find out if the drug is safe and effective, possibly offering a new option when standard treatments fail.
This trial tests a new drug, AK112, combined with chemotherapy for people with advanced non-squamous non-small cell lung cancer that has spread to the lining of the lung (malignant pleural effusion). The goal is to see if this combination helps shrink tumors and improve outcomes.
Hear when a new Brain Metastasases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.